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Background: In the PREVA study of chronic cluster head-
ache (cCH) prophylaxis, attack frequency reductions from
baseline were significantly more pronounced with non-
invasive vagus nerve stimulation (gammaCore) plus stan-
dard of care (nVNSþ SoC) than with SoC alone.
Aim: To evaluate the time to and magnitude of nVNS
benefits in PREVA ad hoc analyses.
Methods: Subjects received SoC during the 2-week base-
line period followed by nVNSþ SoC or SoC alone during
the 4-week randomised phase (RP). In the optional 4-week
extension phase (EP), all subjects received nVNSþ SoC.
The nVNS treatment comprised three 2-minute stimula-
tions administered twice daily (6 stimulations total per
day).
Results: Mean weekly attack frequency was significantly
lower with nVNSþ SoC than with SoC alone from RP
week 2 through EP week 3; this difference diminished by
EP week 4 (Figure). For the nVNSþ SoC group, attack
frequency was significantly lower at RP week 1 through
EP week 4 than at baseline and was relatively stable
during the EP. Response rates were significantly greater
with nVNSþ SoC than with SoC alone when response
was defined as attack frequency reductions of 25%,
50%, and 75% from baseline (P 0.01).
Conclusions: Prophylactic nVNS led to rapid, significant,
and sustained reductions in cCH attack frequency as early
as 2 weeks after addition to SoC and was associated with
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